溫州康寧

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120

Contents

Corporate Information

Executive Directors

Non-executive Directors

Independent Non-executive Directors

Audit Committee

Nomination Committee

Remuneration Committee

Strategy and Risk Management Committee

Supervisory Committee

Joint Company Secretaries

Authorized Representatives

Auditor

Corporate Information

Financial Highlights

	For the year ended December 31,				
	2023	[illegible]	[illegible]	[illegible]	[illegible]
	RMB'000	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	1,596,266	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	99,182	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	12,250	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	86,932	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	85,948	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	984	[illegible]	[illegible]	[illegible]	[illegible]

	As of December 31,				
	2023	[illegible]	[illegible]	[illegible]	[illegible]
	RMB'000	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	3,047,687	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	1,639,481	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	1,408,206	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	1,265,065	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	143,141	[illegible]	[illegible]	[illegible]	[illegible]

Chairman's Statement

Chairman's Statement

Management Discussion and Analysis

Psychiatric Specialized Medical Service Industry and Geriatric Healthcare Industry in China

Management Discussion and Analysis

Management Discussion and Analysis

Management Discussion and Analysis

Management Discussion and Analysis

Management Discussion and Analysis

Management Discussion and Analysis

Business Review

守正創新 穩中求進

Management Discussion and Analysis

《辦公廳關於發展銀髮經濟增進老年人福祉的意見》國辦發 / . 號

Business Highlights

Management Discussion and Analysis

Financial Review

[illegible]

[illegible]

[illegible]

	For the year ended December 31,	
	2023	[illegible]
	(RMB'000)	[illegible]
[illegible]	1,485,161	[illegible]
[illegible]	105,756	[illegible]
[illegible]	5,349	[illegible]
Total revenue	1,596,266	[illegible]

[illegible]

[illegible] **Billing Revenue** [illegible]

Management Discussion and Analysis

[illegible]

	For the year ended December 31, 2023 (RMB'000)	[illegible]
[illegible]	1,537,406	[illegible]
[illegible]	52,245	[illegible]
[illegible]	1,485,161	[illegible]

[illegible]

Management Discussion and Analysis

	For the year ended December 31,	
	2023	[illegible]
	(RMB'000)	[illegible]
Billing Revenue from owned hospitals	1,537,406	[illegible]
[illegible]	1,107,920	[illegible]
[illegible]	429,486	[illegible]

Management Discussion and Analysis

[illegible]

	For the year ended December 31,	
	2023	[illegible]
Inpatients		
[illegible]	11,268	[illegible]
[illegible]	4,112,820	[illegible]
[illegible]	84.4	[illegible]
[illegible]	3,471,366	[illegible]
[illegible]	1,146,473	[illegible]
[illegible]		
[illegible]	330	[illegible]
[illegible]	172,590	[illegible]
[illegible]	50	[illegible]
Total inpatient revenue ***(RMB'000)***	1,319,063	[illegible]
Total average inpatient spending per bed-day ***(RMB)***	380	[illegible]
Outpatients		
[illegible]	500,570	[illegible]
[illegible]	68,199	[illegible]
[illegible]		
[illegible]	136	[illegible]
[illegible]	150,144	[illegible]
[illegible]	300	[illegible]
Total outpatient revenue ***(RMB'000)***	218,343	[illegible]
Total average outpatient spending per visit ***(RMB)***	436	[illegible]
Total treatment and general healthcare services revenue ***(RMB'000)***	1,214,672	[illegible]
Total pharmaceutical sales revenue ***(RMB'000)***	322,734	[illegible]

Management Discussion and Analysis

[illegible]

	For the year ended December 31,	
	2023	[illegible]
	(RMB'000)	[illegible]
[illegible]	365,896	[illegible]
[illegible]	435,287	[illegible]
[illegible]	31,319	[illegible]
[illegible]	89,752	[illegible]
[illegible]	65,183	[illegible]
[illegible]	21,092	[illegible]
[illegible]	99,391	[illegible]
Cost of revenue of owned hospitals	1,107,920	[illegible]

Management Discussion and Analysis

Management Discussion and Analysis

	For the year ended December 31,	
	2023	[illegible]
	(RMB'000)	[illegible]
[illegible]	117,426	[illegible]
[illegible]	29,101	[illegible]
[illegible]	19,853	[illegible]
[illegible]	4,725	[illegible]
[illegible]	41,921	[illegible]
Total administrative expenses	213,026	[illegible]

Management Discussion and Analysis

[illegible]

	For the year ended December 31,	
	2023	[illegible]
	(RMB'000)	[illegible]
[illegible]	20,552	[illegible]
[illegible]	8,436	[illegible]
[illegible]	3,427	[illegible]
[illegible]	51	[illegible]
Total	32,466	[illegible]

[illegible]

[illegible]

	For the year ended December 31,	
	2023	[illegible]
	(RMB'000)	[illegible]
[illegible]	-5,266	[illegible]
[illegible]	-4	[illegible]
[illegible]	30,180	[illegible]
[illegible]	9,755	[illegible]
[illegible]	5,694	[illegible]
[illegible]	1,093	[illegible]
Finance expenses – net	41,452	[illegible]

Management Discussion and Analysis

	For the year ended December 31,	
	2023	
	(RMB'000)	
	-6,465	
	698	
	-300	
	–	
	-6,067	

Management Discussion and Analysis

[illegible]

[illegible]

	For the year ended December 31,	
	2023	[illegible]
	(RMB'000)	(RMB'000)
[illegible]	566	[illegible]
[illegible]	5,975	[illegible]
[illegible]	3,004	[illegible]
Non-operating income	9,545	[illegible]
[illegible]	291	[illegible]
[illegible]	4,494	[illegible]
[illegible]	3,380	[illegible]
[illegible]	3,201	[illegible]
Non-operating expenses	11,816	[illegible]

[illegible]

[illegible]

[illegible]

Management Discussion and Analysis

Financial Position

Management Discussion and Analysis

Liquidity and Capital Resources

	For the year ended December 31,	
	2023 (RMB'000)	[illegible]
[illegible]	265,033	[illegible]
[illegible]	-215,017	[illegible]
[illegible]	96,107	[illegible]
[illegible]	146,127	[illegible]

Management Discussion and Analysis

Indebtedness

Management Discussion and Analysis

Management Discussion and Analysis

Equity Incentive Scheme

Management Discussion and Analysis

Management Discussion and Analysis

Management Discussion and Analysis

Management Discussion and Analysis

重點激勵、有效激勵

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Closing Price before the Date of Grant (HKD)	Vesting Date (Unlocking Date)	Grant Price (RMB)	Balance of Incentive Shares Granted but not Vested as at January 1, 2023	Balance of Incentive Shares Granted and Vested as at January 1, 2023	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at December 31, 2023
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Closing Price before the Date of Grant (HKD)	Vesting Date (Unlocking Date)	Grant Price (RMB)	Balance of Incentive Shares Granted but not Vested as at January 1, 2023	Balance of Incentive Shares Granted and Vested as at January 1, 2023	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at December 31, 2023
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]					
Total					–	2,454,632	–	–	–	–	–

Management Discussion and Analysis

Management Discussion and Analysis

Report of the Board

Report of the Board

《中華人民共和國精神衛生法》

《中華人民共和國基本醫療衛生與健康促進法》

《醫療機構管理條例》

《醫療機構管理條例實施細則》

Report of the Board

Report of the Board

Report of the Board

Report of the Board

Executive Directors

Non-executive Directors

Independent Non-executive Directors

Report of the Board

Report of the Board

Report of the Board

[illegible]

Name of Directors	Class of Shares	Nature of Interest	Number of Shares	Total Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]			
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]			
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

[illegible]

[illegible] 上海金浙企業管理中心 有限合夥 [illegible] 上海金浙企業管理中心 有限合夥 [illegible]

Report of the Board

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
中央企業鄉村產業投資基金股份有限公司	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
上海金浙企業管理中心(有限合夥)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
上海金浦健服股權投資管理有限公司	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
溫州金寧股權投資合夥企業(有限合夥)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
上海檀英投資合夥企業(有限合夥)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Report of the Board

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
[illegible] 上海樂進投資合夥企業(有限合夥)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] 上海正心谷投資管理有限公司	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] 萬得信息技術股份有限公司	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] 上海荷花緣企業管理中心(有限合夥)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] 萬得影響力股權投資(嘉興)合夥企業(有限合夥)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] 中信証券投資有限公司	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] 鄒海麗	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Report of the Board

Report of the Board

For determining the entitlement to attend and vote at the AGM

BDO

Report of the Board

PwC

Report of the Supervisory Committee

Corporate Governance Report

Value

Vision

Mission

Corporate Governance Report

Board Composition

Corporate Governance Report

Corporate Governance Report

Corporate Governance Report

Companies Ordinance

Accounting Policies

the Accounting Standards for Business Enterprises

Enterprises

Corporate Governance Report

Changes of Significant Accounting Policies

Name of Directors	Number of Board meetings convened/attended
Executive Directors	
Non-executive Directors	
Independent non-executive Directors	

Corporate Governance Report

Name of Directors	Number of general meetings convened/attended
Executive Directors	
Non-executive Directors	
Independent non-executive Directors	

Corporate Governance Report

Directors	Number of meetings convened/attended

Corporate Governance Report

Directors	Number of meetings convened/attended

Corporate Governance Report

Directors	Number of meetings convened/attended
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]

Corporate Governance Report

Directors	Number of meetings convened/attended

Corporate Governance Report

The Current Composition of the Board

Age	Gender	Years of service as Director

（《招錄管理辦法》）

Corporate Governance Report

Corporate Governance Report

Corporate Governance Report

Remuneration band (RMB)	Number of individuals
[illegible]	[illegible]
[illegible]	[illegible]

Corporate Governance Report

Corporate Governance Report

Corporate Governance Report

Directors, Supervisors and Senior Management

Executive Directors

Mr. GUAN Weili 管偉立 ... 溫州市精神病院 ... 溫州醫科大學 ... 溫州醫學院 ... 溫州市人事局 ...

Ms. WANG Lianyue 王蓮月 ... 溫州市精神病院 ... 溫州醫科大學 ... 溫州醫學院 ... 中共溫州市委黨校 ... 西安交通大學網絡教育學院 ... 中歐國際工商學院 ... 二級心理諮詢師 ... 人力資源和社會保障部 ...

Directors, Supervisors and Senior Management

Mr. WANG Jian 王健 … 科員 … 副主任科員 … 中國證券監督管理委員會廈門監管局 … 安永華明會計師事務所 特殊普通合夥 …

… 北京大學光華管理學院 … 註冊會計師非執業會員 …

Directors, Supervisors and Senior Management

Non-executive Directors

Mr. QIN Hao 秦浩 … 上海正心谷投資管理有限公司 …

Mr. LI Changhao 李昌浩 … 國投創益產業基金管理有限公司 … 寧夏銀星能源股份有限公司 … 西部黃金股份有限公司 … 雲南鋁業股份有限公司 …

Directors, Supervisors and Senior Management

Independent Non-executive Directors

Ms. ZHONG Wentang 鍾文堂 上海信公企業管理諮詢有限公司

Directors, Supervisors and Senior Management

Mr. XU Ning 許寧 … 溫州電視台 … 《溫州新聞聯播》 …

… 北京廣播學院 … 中國傳媒大學 … 一級人力資源管理師 …

Mr. XU Yongjiu 徐永久 … 上海金浦健服股權投資管理有限公司 … 溫州金寧股權投資合夥企業 有限合夥 … 金浦產業投資基金管理有限公司 … 上海金浦健服股權投資管理有限公司 …

Directors, Supervisors and Senior Management

Mr. QIAN Chengliang 錢成良 … 溫州市人大常委會 … 麗水市委常委 …

Mr. XIE Tiefan 謝鐵凡 …

… 中央廣播電視大學 … 江西省井崗山大學 … 溫州市人事局 …

Ms. ZHANG Yue 張玥 …

Directors, Supervisors and Senior Management

Mr. ZHOU Chaoyi 周朝毅 … 溫州心血管醫院 … 科長 … 溫州市中醫院 … 溫州市氣功療養院 …

Mr. YE Minjie 葉敏捷 … 科長 … 溫州市精神病院 …

… 新鄉醫學院 … 浙江省人力資源和社會保障廳 …

Directors, Supervisors and Senior Management

Mr. XU Yi 徐誼 … 科長 … 中共溫州市委黨校 …

… 浙江大學 …

Ms. ZHANG Feixue 章飛雪 … 樂清市第五人民醫院 …

… 北京中醫藥大學 … 浙江大學現代衛生管理高級研修班 … 浙江師範大學 … 浙江省人力資源和社會保障廳 …

Directors, Supervisors and Senior Management

Mr. WANG Jian 王健

Mr. JIN Weiguang 金偉光

溫州市衛生局

中央黨校函授學院

浙江師範大學區域經濟研究生課程進修班

澳大利亞衛生行政管理 醫療質量管理 培訓班

浙江大學公共管理研修班

Directors, Supervisors and Senior Management

Mr. JIN Hui 金輝 … 浙江華明會計師事務所有限公司 … 溫州立德會計師事務所有限公司 …

… 浙江財經大學 …

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office

Auditor's Report

To the Shareholders of Wenzhou Kangning Hospital Co., Ltd.,

Auditor's Report

Key Audit Matters	How we addressed the key audit matter

Auditor's Report

Auditor's Report

Auditor's Report

Consolidated Balance Sheets

ASSETS	S	Balance as at the end of the period	0

Consolidated Balance Sheets

LIABILITIES AND SHAREHOLDERS' EQUITY	Balance as at the end of the period		
Current liabilities:			

Parent Company Balance Sheets

ASSETS	Note	Balance as at the end of the period	[illegible]
Current assets:			
[illegible]		186,837,559.21	[illegible]
[illegible]	[illegible]	48,066,557.69	[illegible]
[illegible]		228,131.12	[illegible]
[illegible]	[illegible]	600,448,325.58	[illegible]
[illegible]		11,181,002.59	[illegible]
[illegible]		330,000.00	[illegible]
Total current assets		847,091,576.19	[illegible]
Non-current assets:			
[illegible]	[illegible]	785,983,439.17	[illegible]
[illegible]		65,099,055.34	[illegible]
[illegible]		288,701,322.35	[illegible]
[illegible]		113,600.00	[illegible]
[illegible]		23,680,002.23	[illegible]
[illegible]		18,459,271.72	[illegible]
[illegible]		14,608,690.36	[illegible]
[illegible]		6,320,388.26	[illegible]
Total non-current assets		1,202,965,769.43	[illegible]
TOTAL ASSETS		2,050,057,345.62	[illegible]

Parent Company Balance Sheets

LIABILITIES AND SHAREHOLDERS' EQUITY		Balance as at the end of the period	
Current liabilities:			
		125,000,000.00	[illegible]
		33,774,329.53	[illegible]
		4,172,410.35	[illegible]
		20,572,854.31	[illegible]
		1,603,746.33	[illegible]
		38,919,608.73	[illegible]
		173,615,500.00	[illegible]
Total current liabilities		397,658,449.25	[illegible]
Non-current liabilities:			
		362,042,127.25	[illegible]
		25,855,234.63	[illegible]
		8,734,099.00	[illegible]
Total non-current liabilities		396,631,460.88	[illegible]
Total liabilities		794,289,910.13	[illegible]

Parent Company Balance Sheets

LIABILITIES AND SHAREHOLDERS' EQUITY		Balance as at the end of the period	
Shareholders' equity:			
		74,600,300.00	[illegible]
		871,230,628.64	[illegible]
		12,587,011.74	
		38,399,577.13	[illegible]
		284,123,941.46	[illegible]
Total shareholders' equity		1,255,767,435.49	[illegible]
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		2,050,057,345.62	[illegible]

Consolidated Income Statement

Item		Amount for the current period	
I. Total revenue		1,596,265,532.13	[illegible]
		1,596,265,532.13	[illegible]
II. Total cost of sales		1,495,651,128.76	[illegible]
		1,185,129,954.78	[illegible]
		6,474,904.42	[illegible]
		17,102,355.09	[illegible]
		213,025,707.14	[illegible]
		32,466,196.15	[illegible]
		41,452,011.18	[illegible]
		39,936,115.20	[illegible]
		5,265,571.27	[illegible]
		15,976,715.23	[illegible]
		-6,067,197.23	[illegible]
		-6,465,278.89	[illegible]
		214,405.20	[illegible]
		-9,354,735.55	[illegible]
			[illegible]
		68,088.99	[illegible]

Consolidated Income Statement

Item		Amount for the current period	
III. Operating profit (losses represented with “-” signs)		101,451,680.01	[illegible]
[illegible]		9,545,446.16	[illegible]
[illegible]		11,815,508.86	[illegible]
IV. Total profit (total losses represented with “-” signs)		99,181,617.31	[illegible]
[illegible]		12,250,009.49	[illegible]
V. Net profit (net losses represented with “-” signs)		86,931,607.82	[illegible]
[illegible]			
[illegible]		86,931,607.82	[illegible]
[illegible]			
[illegible]		85,947,806.64	[illegible]
[illegible]		983,801.18	[illegible]
VI. Other comprehensive income, net of tax			
[illegible]			

Consolidated Income Statement

Item		Amount for the current period	
VII. Total comprehensive income		86,931,607.82	
		85,947,806.64	
		983,801.18	
VIII. Earnings per share:			
		1.15	
		1.15	

Parent Company Income Statement

Item		Note	Amount for the current period	
I.	Revenue		387,325,861.90	[illegible]
			269,941,680.92	[illegible]
			455,531.13	[illegible]
			954,503.04	[illegible]
			76,405,750.06	[illegible]
			20,551,838.32	[illegible]
			13,355,222.49	[illegible]
			24,083,867.34	[illegible]
			15,119,285.04	[illegible]
			2,686,378.93	[illegible]
			34,292,572.00	[illegible]
			1,538,932.70	[illegible]
			1,982,203.29	[illegible]
			-2,576,210.65	[illegible]
			39,085.15	[illegible]
II.	Operating profit (losses represented with “-” signs)		42,085,364.66	[illegible]
			8,106,945.59	[illegible]
			1,844,670.16	[illegible]
III.	Total profit (total losses represented with “-” signs)		48,347,640.09	[illegible]
			-1,370,722.10	[illegible]
IV.	Net profit (net losses represented with “-” signs)		49,718,362.19	[illegible]
			49,718,362.19	[illegible]

Parent Company Income Statement

Item		Amount for the current period	
V. Other comprehensive income, net of tax			
(II) Other comprehensive income that can be reclassified to profit and loss			
VI. Total comprehensive income		49,718,362.19	
VII. Earnings per share:			

Consolidated Cash Flow Statement

Item		Amount for the current period	
I. Cash flows from operating activities			
		1,563,715,823.56	
		215,257,897.46	
Sub-total of cash inflows of operating activities		1,778,973,721.02	
		534,160,766.19	
		588,242,659.36	
		54,415,007.31	
		337,122,050.70	

Consolidated Cash Flow Statement

Item		Amount for the current period	
II. Cash flows from investing activities			
		8,279,457.77	
			[illegible]
		2,924,936.67	[illegible]
	[illegible]	1,248,000.00	
Sub-total of cash inflows of investing activities		12,452,394.44	[illegible]
		179,732,393.77	[illegible]
		2,447,872.75	
		31,289,153.32	[illegible]
	[illegible]	14,000,059.94	[illegible]
Sub-total of cash outflows of investing activities		227,469,479.78	[illegible]
Net cash flows from investing activities		-215,017,085.34	[illegible]

Consolidated Cash Flow Statement

Item	[illegible]	Amount for the current period	[illegible]
III. Cash flows from financing activities			
[illegible]		2,999,500.00	[illegible]
[illegible]			
[illegible]		2,999,500.00	[illegible]
[illegible]		605,774,669.65	[illegible]
[illegible]	[illegible]	55,900,000.00	[illegible]
Sub-total of cash inflows of financing activities		664,674,169.65	[illegible]
[illegible]		357,677,872.75	[illegible]
[illegible]		35,398,808.90	[illegible]
[illegible]			
[illegible]		3,001,920.88	
[illegible]	[illegible]	175,490,616.99	[illegible]
Sub-total of cash outflows of financing activities		568,567,298.64	[illegible]
Net cash flows from financing activities		96,106,871.01	[illegible]
IV. Effect of foreign exchange rate changes on cash and cash equivalents		4,325.27	[illegible]
V. Net increase in cash and cash equivalents		146,127,348.40	[illegible]
[illegible]	[illegible]	258,595,990.97	[illegible]
VI. Cash and cash equivalents at the end of the period	[illegible]	404,723,339.37	[illegible]

Parent Company Cash Flow Statement

Item	[illegible]	Amount for the current period	[illegible]
I. Cash flows from operating activities			
[illegible]		388,171,338.58	[illegible]
[illegible]		677,755,040.34	[illegible]
Sub-total of cash inflows of operating activities		1,065,926,378.92	[illegible]
[illegible]		132,581,733.32	[illegible]
[illegible]		155,983,637.05	[illegible]
[illegible]		1,125,964.24	[illegible]
[illegible]		662,158,585.72	[illegible]
Sub-total of cash outflows of operating activities		951,849,920.33	[illegible]
Net cash flows from operating activities		114,076,458.59	[illegible]
II. Cash flows from investing activities			
[illegible]		16,657,744.50	[illegible]
[illegible]		45,000,000.00	[illegible]
[illegible]		714,238.30	[illegible]
[illegible]			
[illegible]		108,521,408.71	
Sub-total of cash inflows of investing activities		170,893,391.51	[illegible]
[illegible]		6,217,731.13	[illegible]
[illegible]		54,194,772.75	[illegible]
[illegible]			
[illegible]		164,426,250.04	
Sub-total of cash outflows of investing activities		224,838,753.92	[illegible]
Net cash flows from investing activities		-53,945,362.41	[illegible]

Parent Company Cash Flow Statement

Item		Amount for the current period	
III. Cash flows from financing activities			
		440,050,000.00	
		19,000,000.00	

Sub-toibutofconed inm finaofc/activities 440,050,005900

Consolidated Statement of Changes in Owners' Equity

Items	Amount for the current period													
	Equity attributable to owners of the parent company													
		Other equity instruments												
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings	Subtotal	Non-controlling interests	Total owners' equity
I. Balance as at the end of the previous year	[illegible]				[illegible]				[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
II. Balance as at the beginning of the current year	[illegible]				[illegible]				[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
III. Increases/decreases in the current period ("–" for decreases)					[illegible]	[illegible]					[illegible]	[illegible]	[illegible]	[illegible]
[illegible]											[illegible]	[illegible]	[illegible]	[illegible]
[illegible]						[illegible]						[illegible]	[illegible]	[illegible]
[illegible]						[illegible]						[illegible]	[illegible]	[illegible]
[illegible]											[illegible]	[illegible]	[illegible]	[illegible]
[illegible]											[illegible]	[illegible]	[illegible]	[illegible]

Consolidated Statement of Changes in Owners' Equity

Items	Amount for the current period													
	Equity attributable to owners of the parent company													
		Other equity instruments												
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings	Subtotal	Non-controlling interests	Total owners' equity
[illegible]														
(V) Special reserves														
[illegible]														
[illegible]														
(VI) Others					[illegible]							[illegible]		[illegible]
IV. Balance as at the end of the period	[illegible]				[illegible]	[illegible]			[illegible]		[illegible]	[illegible]	[illegible]	[illegible]

Consolidated Statement of Changes in Owners' Equity

I. Balance as at the end of the previous year	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
II. Balance as at the beginning of the current year	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
III. Increases/decreases in the current period ("–" for decreases)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Consolidated Statement of Changes in Owners' Equity

(V) Special reserves

(VI) Others

IV. Balance as at the end of the period

Statement of Changes in Parent Company Owners' Equity

Items	Amount for the current period										
	Share capital	Other equity instruments: Preferred shares	Other equity instruments: Perpetual bonds	Other equity instruments: Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Retained earnings	Total owners' equity
I. Balance as at the end of the previous year	[illegible]				[illegible]				[illegible]	[illegible]	[illegible]
II. Balance as at the beginning of the current year	[illegible]				[illegible]				[illegible]	[illegible]	[illegible]
III. Increases/decreases in the current period ("–" for decreases)						[illegible]				[illegible]	[illegible]
[illegible]										[illegible]	[illegible]
[illegible]						[illegible]					[illegible]
[illegible]						[illegible]					[illegible]
[illegible]										[illegible]	[illegible]
[illegible]										[illegible]	[illegible]
[illegible]	[illegible]				[illegible]	[illegible]			[illegible]	[illegible]	[illegible]

Statement of Changes in Parent Company Owners' Equity

I. Balance as at the end of the previous year	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
II. Balance as at the beginning of the current year	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
III. Increases/decreases in the current period ("–" for decreases)		[illegible]		[illegible]	[illegible]
				[illegible]	[illegible]
		[illegible]			[illegible]
		[illegible]			[illegible]
		[illegible]			[illegible]
IV. Balance as at the end of the period	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

溫州市康寧精神康復醫院

溫州康寧醫院股份有限公司

Notes to the Financial Statements

(I) Basis of preparation

(II) Going concern

Notes to the Financial Statements

(I) Statement of compliance with the Accounting Standards for Business Enterprises

(II) Accounting period

(III) Operating cycle

(IV) Recording currency

(V) Accounting treatments for business combinations under common control and not under common control

Notes to the Financial Statements

(V) Accounting treatments for business combinations under common control and not under common control

(VI) The criterion of control and preparation of consolidated financial statements

Notes to the Financial Statements

(VI) The criterion of control and preparation of consolidated financial statements

Notes to the Financial Statements

(VI) The criterion of control and preparation of consolidated financial statements

①

Notes to the Financial Statements

(VI) The criterion of control and preparation of consolidated financial statements

Notes to the Financial Statements

(VI) The criterion of control and preparation of consolidated financial statements

(VII) Classification of joint arrangement and accounting treatment of joint operation

Notes to the Financial Statements

(VIII) Determination standards of cash and cash equivalents

(IX) Foreign currency transactions and translation of foreign currency statements

(X) Financial instruments

Notes to the Financial Statements

(X) **Financial instruments**

Notes to the Financial Statements

(X) Financial instruments

Notes to the Financial Statements

(X) Financial instruments

Notes to the Financial Statements

(X) Financial instruments

Notes to the Financial Statements

(X) Financial instruments

Notes to the Financial Statements

(X) **Financial instruments**

Notes to the Financial Statements

(X) Financial instruments

Notes to the Financial Statements

(X) Financial instruments

Items	Grouping categories	Basis for determining

Notes to the Financial Statements

(XI) Inventories

Notes to the Financial Statements

(XII) Contract assets

(XIII) Long-term equity investments

Notes to the Financial Statements

(XIII) Long-term equity investments

(XIII) Long-term equity investments

(XIII) Long-term equity investments

(XIII) Long-term equity investments

Notes to the Financial Statements

(XIV)

Notes to the Financial Statements

(XIV) Fixed assets

Category	Depreciation methods	Depreciation years (years)	Residual value rate (%)	Annual depreciation rates (%)

(XV) Construction in progress

Notes to the Financial Statements

(XVI) Borrowing costs

Notes to the Financial Statements

(XVII) Intangible assets

Item	Estimated useful lives (years)	Amortisation method	Basis

(XVII) Intangible assets

(XVIII) Impairment of long-term assets

Notes to the Financial Statements

(XVIII) Impairment of long-term assets

(XIX) Long-term prepaid expenses

(XX) Contract Liabilities

Notes to the Financial Statements

(XXI) Employee benefits

Notes to the Financial Statements

(XXI) Employee benefits

Notes to the Financial Statements

(XXII) Provisions

Notes to the Financial Statements

(XXIII) Share-based payments

(XXIII) Share-based payments

(XXIV) Revenue

Notes to the Financial Statements

(XXIV) Revenue

Notes to the Financial Statements

(XXIV) Revenue

(XXIV) **Revenue**

(XXV) **Contract costs**

Notes to the Financial Statements

(XXV) Contract costs

(XXVI) Government grants

Notes to the Financial Statements

(XXVI) Government grants

(XXVII) Deferred tax assets and deferred tax liabilities

Notes to the Financial Statements

(XXVII) Deferred tax assets and deferred tax liabilities

Notes to the Financial Statements

(XXVII) Deferred tax assets and deferred tax liabilities

(XXVIII) Lease

Notes to the Financial Statements

(XXVIII) Lease

Notes to the Financial Statements

(XXVIII) Lease

Notes to the Financial Statements

(XXVIII) Lease

Notes to the Financial Statements

(XXVIII) Lease

Notes to the Financial Statements

(XXVIII) Lease

Notes to the Financial Statements

(XXVIII) Lease

(XXIX) Repurchase of the Company's shares

Notes to the Financial Statements

(XXX) Determination methodology and selection basis of the materiality criteria

Items	Materiality Criteria

Notes to the Financial Statements

(XXXI) Significant accounting estimates and judgements

(XXXI) Significant accounting estimates and judgements

Items	Evaluation Parameters in the current period

Notes to the Financial Statements

(XXXII) Changes in significant accounting policies and accounting estimates

Notes to the Financial Statements

(XXXII) Changes in significant accounting policies and accounting estimates

(I) Major tax categories and tax rates

Tax categories	Tax basis	Tax rate

Taxpayer	Income tax rate

Notes to the Financial Statements

(I) Cash at bank and on hand

Items	Balance as at the end of the period	[illegible]
[illegible]	371,623.69	[illegible]
[illegible]	416,980,298.98	[illegible]
[illegible]	1,509,798.72	[illegible]
[illegible]	418,861,721.39	[illegible]

(II) Financial assets held for trading

Items	Balance as at the end of the period	[illegible]
[illegible]	7,350,298.53	[illegible]
[illegible]	7,350,298.53	[illegible]
[illegible]	7,350,298.53	[illegible]

(III) Accounts receivable

Aging	Balance as at the end of the period	[illegible]
[illegible]	425,833,221.01	[illegible]
[illegible]	6,696,709.84	[illegible]
[illegible]	4,480,032.80	[illegible]
[illegible]	7,780,009.57	[illegible]
[illegible]	444,789,973.22	[illegible]
[illegible]	24,348,903.66	[illegible]
[illegible]	420,441,069.56	[illegible]

Notes to the Financial Statements

(III) Accounts receivable

	Balance as at the end of the period				
	Book balance		Provision for bad debts		
	Amount	Proportion (%)	Amount	Proportion	Book value

(III) Accounts receivable

Items	Book balance	Provision for bad debts	Proportion of provision (%)	Reason for the provision		
	Balance as at the end of the period					
	19,507,030.88	12,854,582.28	65.90	Provision for bad debts based on Lifetime ECL		
	19,507,030.88	12,854,582.28	/	/		

Items	Accounts receivable	Provision for bad debt	Proportion of provision (%)
	Balance as at the end of the period		
	425,282,942.34	11,494,321.38	2.70
	425,282,942.34	11,494,321.38	/

Notes to the Financial Statements

(III) Accounts receivable

Category						Balance as at the end of the period
						12,854,582.28
						11,494,321.38
						24,348,903.66

(IV) Advances to suppliers

Aging	Balance as at the end of the period Amount	Proportion (%)		
	9,048,941.18	92.05		
	742,811.80	7.56		
	6,000.00	0.06		
	32,800.00	0.33		
	9,830,552.98	100.00		

(V) Other receivables

Items	Balance as at the end of the period	
	69,705,728.98	
	69,705,728.98	

Aging	Balance as at the end of the period	
	53,412,990.26	
	29,894,811.69	
	8,912,677.15	
	5,404,423.07	
	742,744.83	
	3,885,239.68	
	102,252,886.68	
	32,547,157.70	
	69,705,728.98	

Notes to the Financial Statements

(V) Other receivables

Category	Balance as at the end of the period: Book balance: Amount	Proportion (%)	Provision for bad debts: Amount	Proportion of provision (%)	Book value	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	37,404,736.41	36.58	30,697,494.28	82.07	6,707,242.13	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	23,709,977.64	23.19	17,002,735.51	71.71	6,707,242.13	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	10,204,311.69	9.98	10,204,311.69	100.00						
汪長勝	3,490,447.08	3.41	3,490,447.08	100.00						
[illegible]	64,848,150.27	63.42	1,849,663.42	2.85	62,998,486.85	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	64,848,150.27	63.42	1,849,663.42	2.85	62,998,486.85	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	102,252,886.68	100.00	32,547,157.70		69,705,728.98	[illegible]	[illegible]	[illegible]		[illegible]

Notes to the Financial Statements

(V) Other receivables [illegible]

[illegible]

Name	Book balance	Provision for bad debts	Proportion of provision (%)	Reason for the provision	[illegible]
[illegible]	23,709,977.64	17,002,735.51	71.71	The allowance for losses is measured against expected credit loss in the whole duration	[illegible]
[illegible]	10,204,311.69	10,204,311.69	100.00	Expected to be hard to recover	
汪長勝	3,490,447.08	3,490,447.08	100.00	Expected to be hard to recover	
[illegible]	37,404,736.41	30,697,494.28	/	/	[illegible]

[illegible]

Name	Other receivables	Provision for bad debts	Proportion of provision (%)
[illegible]	64,848,150.27	1,849,663.42	2.85
[illegible]	64,848,150.27	1,849,663.42	

[illegible]

Notes to the Financial Statements

(V) Other receivables

Provision for bad debts	Stage I 12-month ECL	Stage II Lifetime ECL (not credit impaired)	Stage III Lifetime ECL (credit impaired)	Total
[illegible]	[illegible]		[illegible]	[illegible]
[illegible]				
[illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
[illegible]	[illegible]		[illegible]	[illegible]
[illegible]				
[illegible]				
[illegible]	[illegible]			[illegible]
[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]		[illegible]	[illegible]

Notes to the Financial Statements

(V) Other receivables

0SS	Stage I 12-month ECL	Stage II Lifetime ECL (not credit impaired)	Stage III Lifetime ECL (credit impaired)	Total
[illegible]	[illegible]		[illegible]	[illegible]
[illegible]				
[illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
[illegible]	[illegible]		[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]		[illegible]	[illegible]

(V) Other receivables

[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	Balance as at the end of the period
[illegible]	[illegible]	[illegible]		[illegible]	30,697,494.28
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	1,849,663.42
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	32,547,157.70

Item	Amount written-off
[illegible]	[illegible]

Nature of receivables	Book balance as at the end of the period	[illegible]
[illegible]	22,266,761.49	[illegible]
[illegible]	19,150,000.00	
	4,818,862.51	[illegible]
	51,045.33	[illegible]
[illegible]	52,887,698.31	[illegible]
	3,078,519.04	[illegible]
[illegible]	102,252,886.68	[illegible]

(VI) Inventories

Category	Book balance	Provision for decline in the value of inventories/ impairment provision for contract performance costs	Book value
	Balance as at the end of the period		
S	1,616,778.62		1,616,778.62

(IX) Long-term equity investments

	Balance as at the end of the previous year	Balance of the impairment provision as at the end of the previous year	Increase/decrease in the current period: Increase in investment					Balance as at the end of the period	
Associates									
[illegible]	[illegible]			[illegible]				[illegible]	
[illegible]	[illegible]			[illegible]				[illegible]	
[illegible]	[illegible]			[illegible]				[illegible]	
[illegible]	[illegible]			[illegible]				[illegible]	
[illegible]	[illegible]			[illegible]				[illegible]	
[illegible]			[illegible]	[illegible]			[illegible]	[illegible]	
[illegible]	[illegible]			[illegible]			[illegible]		
[illegible]	[illegible]		[illegible]	[illegible]			[illegible]	[illegible]	

[illegible]

Notes to the Financial Statements

(X) Other non-current financial assets

Items	Balance as at the end of the period	[illegible]
[illegible]	65,099,055.34	[illegible]
	65,099,055.34	[illegible]
[illegible]	65,099,055.34	[illegible]

(XI) Fixed assets

Items	Balance as at the end of the period	[illegible]
[illegible]	794,856,342.94	[illegible]
[illegible]	794,856,342.94	[illegible]

(XI) Fixed assets

Items	Buildings and structure	Medical equipment	Motor vehicles	Electronic and other equipment	Fixed assets leased under sale-and-leaseback finance leases	Total
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]
[illegible]	[illegible]	[illegible]		[illegible]		[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]
	[illegible]				[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]				[illegible]		[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]
	[illegible]	[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]				[illegible]		[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

(XI) Fixed assets

Items	Buildings and structure	Medical equipment	Motor vehicles	Electronic and other equipment	Fixed assets leased under sale-and-leaseback finance leases	Total
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

[illegible]

(XII) Construction in progress

[illegible]

Items	Balance as at the end of the period Book balance	Impairment provision	Book value	[illegible]	[illegible]	[illegible]
[illegible]	186,980,240.67		186,980,240.67	[illegible]		[illegible]
[illegible]	186,980,240.67		186,980,240.67	[illegible]		[illegible]

[illegible]

Items	Balance as at the end of the period Book balance	Impairment provision	Book value	[illegible]	[illegible]	[illegible]
[illegible]				[illegible]		[illegible]
[illegible]	101,029,929.74		101,029,929.74	[illegible]		[illegible]
[illegible]	85,174,600.41		85,174,600.41	[illegible]		[illegible]
[illegible]				[illegible]		[illegible]
[illegible]				[illegible]		[illegible]
[illegible]	775,710.52		775,710.52	[illegible]		[illegible]
[illegible]	186,980,240.67		186,980,240.67	[illegible]		[illegible]

(XII) Construction in progress

Project name	Budget (RMB'0,000)	Balance as at the end of the previous year	Increase in the current period	Transfer to fixed assets in the current period	Other decrease in the current period	Balance as at the end of the period	Cumulative investment in the construction project as a percentage of the budget (%)	Progress of Construction (%)	Accumulated amount of capitalised interest	Including: Interest capitalised in the current period	Capitalisation rate of interest in the current period (%)	Source of fund
[illegible]	[illegible]	[illegible]	[illegible]			[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]
[illegible]	[illegible]	[illegible]	[illegible]			[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]				[illegible]				[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]			[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]		[illegible]			[illegible]	[illegible]		

Notes to the Financial Statements

(XIII) Right-of-use assets

Items	Buildings and structure	Total
[illegible]		
[illegible]	318,648,155.90	[illegible]
[illegible]	44,432,773.50	[illegible]
[illegible]	44,432,773.50	[illegible]
[illegible]	61,675,817.67	[illegible]
[illegible]	61,455,332.71	[illegible]
[illegible]	220,484.96	[illegible]
[illegible]	301,405,111.73	[illegible]
[illegible]		
[illegible]	128,244,404.32	[illegible]
[illegible]	39,220,377.62	[illegible]
[illegible]	39,220,377.62	[illegible]
[illegible]	55,114,176.89	[illegible]
[illegible]	54,976,373.80	[illegible]
[illegible]	137,803.09	[illegible]
[illegible]	112,350,605.05	[illegible]
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]	189,054,506.68	[illegible]
[illegible]	190,403,751.58	[illegible]

Notes to the Financial Statements

(XIV) Intangible assets

Items	Land use rights	Trademark rights	Software	Medical practice qualifications	Contractual rights to provide management service	Total
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]		[illegible]	[illegible]		[illegible]
[illegible]	[illegible]		[illegible]			[illegible]
[illegible]			[illegible]	[illegible]		[illegible]
[illegible]			[illegible]			[illegible]
[illegible]			[illegible]			[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]			[illegible]			[illegible]
[illegible]			[illegible]			[illegible]
[illegible]			[illegible]			[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(XV) Goodwill

Name of the investees or events generating goodwill	[illegible]	[illegible]	[illegible]	Balance as at the end of the period
[illegible]				
[illegible]	[illegible]			9,271,800.00
[illegible]	[illegible]			690,331.47
[illegible]	[illegible]			1,549,022.38
[illegible]	[illegible]			7,784,850.00
[illegible]	[illegible]			22,987,331.04
[illegible]	[illegible]			151,048.40
[illegible]	[illegible]			5,068,959.78
[illegible]	[illegible]			6,843,288.91
[illegible]	[illegible]			19,416,285.97
[illegible]	[illegible]			51,770,194.67
[illegible]	[illegible]			1,272,643.00
[illegible]	[illegible]		[illegible]	
[illegible]	[illegible]			5,060,323.85
[illegible]		[illegible]		283,528.10
[illegible]		[illegible]		2,502,854.13
[illegible]		[illegible]		9,564,442.65
[illegible]		[illegible]		228,538.31
[illegible]	[illegible]	[illegible]	[illegible]	144,445,442.66
[illegible]				
[illegible]	[illegible]			22,987,331.04
[illegible]	[illegible]			1,549,022.38
[illegible]	[illegible]			24,536,353.42
[illegible]	[illegible]	[illegible]	[illegible]	119,909,089.24

(XV) Goodwill

Name of goodwill asset groups or groups of asset groups	Carrying amount as at the end of the period
	1,531.69
	1,855.94
	1,001.27
	862.51
	4,444.46
	16.16
	646.76
	1,370.56
	4,167.17
	12,983.33
	195.66
	7,016.80
	2,625.28
	2,293.40
	2,962.23
	3.28
	43,976.50

Notes to the Financial Statements

(XV) Goodwill

Key parameters of goodwill impairment test

Asset groups or groups of asset groups	Average number of beds occupied in operation	Average in-patient spending per day per bed (bed/day/yuan)	Perpetuity growth rate	Net profit margin on sales	Pre-tax discount rate
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(XVI) Long-term prepaid expenses

Items	[illegible]	[illegible]	[illegible]	[illegible]	Balance as at the end of the period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	175,706,029.27
[illegible]	[illegible]	[illegible]	[illegible]		178,292.93
[illegible]		[illegible]	[illegible]		26,303.94
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	175,910,626.14

(XVII) Deferred tax assets and deferred tax liabilities

Items	Balance as at the end of the period		[illegible]	
	Deductible temporary differences	Deferred tax assets	[illegible]	[illegible]
[illegible]	25,318,013.56	5,221,670.24	[illegible]	[illegible]
[illegible]	3,073,067.80	3,073,067.80		
[illegible]	126,627,704.89	26,623,506.01	[illegible]	[illegible]
[illegible]	181,046,756.88	45,261,689.23	[illegible]	[illegible]
[illegible]	54,688,502.33	8,203,275.35	[illegible]	[illegible]
[illegible]	390,754,045.46	88,383,208.63	[illegible]	[illegible]

(XVII) Deferred tax assets and deferred tax liabilities (continued)

Items	Balance as at the end of the period: Taxable temporary differences	Balance as at the end of the period: Deferred tax liabilities	Balance as at the end of the previous year	
[illegible]	175,124,829.41	43,659,778.78	[illegible]	[illegible]
[illegible]	15,099,055.33	2,264,858.30	[illegible]	[illegible]
[illegible]	1,565,553.59	306,641.27	[illegible]	[illegible]
[illegible]	177,246,863.48	44,311,715.89		
[illegible]	369,036,301.81	90,542,994.24	[illegible]	[illegible]

Items	As at the end of the period: Offset amount of deferred tax assets and liabilities	As at the end of the period: Balance of deferred tax assets or liabilities after offsetting	[illegible]	[illegible]
[illegible]	43,236,938.03	45,146,270.60		[illegible]
[illegible]	43,236,938.03	47,306,056.21		[illegible]

(XVIII) Other non-current assets

Items	Balance as at the end of the period: Book balance	Impairment provision	Carrying amount	[illegible] Book balance	Impairment provision	Carrying amount
[illegible]	6,034,588.26		6,034,588.26	[illegible]		[illegible]
[illegible]	3,654,622.68		3,654,622.68	[illegible]		[illegible]
[illegible]	9,689,210.94		9,689,210.94	[illegible]		[illegible]

(XIX) Assets with restricted ownership or right-of-use

	As at the end of the period: Book balance	Carrying amount	Types for restriction	Case for restriction	[illegible] Book balance	Carrying amount	Types for restriction	Case for restriction
[illegible]	772,510.54	772,510.54	Freezing	Bank acceptance deposit	[illegible]	[illegible]	[illegible]	[illegible]
	12,000,000.00	12,000,000.00	Freezing	Performance bond	[illegible]	[illegible]	[illegible]	[illegible]
	1,361,750.73	1,361,750.73	Freezing	Foreign Exchange Control Account				
	2,120.75	2,120.75	Freezing	Litigation				
	2,000.00	2,000.00	Freezing	Others				
[illegible]	208,244,700.00	208,244,700.00	Pledge	Pledged loans	[illegible]	[illegible]		[illegible]
	101,426,794.17	19,872,320.31	Mortgage	Sale and leaseback	[illegible]	[illegible]		
	161,856,152.45	156,403,844.80	Mortgage	Secured borrowings	[illegible]	[illegible]	[illegible]	
	59,523,538.00	52,511,079.33	Mortgage	Secured borrowings	[illegible]	[illegible]	[illegible]	
[illegible]	545,189,566.64	451,170,326.46	/	/	[illegible]	[illegible]	/	

Notes to the Financial Statements

(XX) Short-term borrowings

Items	Balance as at the end of the period	[illegible]
[illegible]	125,000,000.00	[illegible]
[illegible]	2,001,700.00	[illegible]
[illegible]	127,001,700.00	[illegible]

(XXI) Financial liabilities held for trading

Items	Balance as at the end of the period	[illegible]
[illegible]	12,400,000.00	[illegible]
[illegible]	12,400,000.00	[illegible]

(XXII) Notes payable

Type	Balance as at the end of the period	[illegible]
[illegible]	1,545,021.09	[illegible]
[illegible]	1,545,021.09	[illegible]

Notes to the Financial Statements

(XXIII) Accounts payable

Items	Balance as at the end of the period	[illegible]
[illegible]	107,790,034.53	[illegible]
[illegible]	1,815,169.24	[illegible]
[illegible]	85,740.32	[illegible]
[illegible]	369,063.58	[illegible]
[illegible]	110,060,007.67	[illegible]

(XXIV) Receipts in advance

Items	Balance as at the end of the period	[illegible]
[illegible]	26,563,603.06	[illegible]
[illegible]	26,563,603.06	[illegible]

(XXV) Employee benefits payable

	[illegible]	[illegible]	[illegible]	Balance as at the end of the period
[illegible]	[illegible]	[illegible]	[illegible]	80,039,461.84
[illegible]	[illegible]	[illegible]	[illegible]	4,284,544.56
[illegible]	[illegible]	[illegible]	[illegible]	84,324,006.40

Notes to the Financial Statements

(XXV) Employee benefits payable (continued)

Items				Balance as at the end of the period
				77,925,215.48
				268,889.28
				1,639,752.64
				1,551,473.36
				87,568.78
				710.50
				205,604.44
				80,039,461.84

Items				Balance as at the end of the period
				4,142,491.99
				142,052.57
				4,284,544.56

Notes to the Financial Statements

(XXVI) Taxes payable

Items	Balance as at the end of the period	
	3,056,261.74	[illegible]
	30,600,774.99	[illegible]
	1,148,089.23	[illegible]
	134,739.29	[illegible]
	2,960,159.04	[illegible]
	96,590.18	[illegible]
	523,438.18	[illegible]
	31,053.22	[illegible]
	1,869.00	[illegible]
	771.60	[illegible]
	38,553,746.47	[illegible]

(XXVII) Other payables

Items	Balance as at the end of the period	
	35,313.43	[illegible]
	624,000.00	[illegible]
	149,611,261.72	[illegible]
	150,270,575.15	[illegible]

Items	Balance as at the end of the period	
	35,313.43	[illegible]
	35,313.43	[illegible]

Notes to the Financial Statements

(XXVII) Other payables (continued)

Items	Balance as at the end of the period	[illegible]
[illegible]	624,000.00	[illegible]
[illegible]	624,000.00	[illegible]

Items	Balance as at the end of the period	[illegible]
[illegible]	62,637,634.31	[illegible]
[illegible]	1,313,457.77	[illegible]
[illegible]	6,766,360.73	[illegible]
[illegible]	1,663,762.95	[illegible]
[illegible]	38,542,529.94	[illegible]
[illegible]	9,845,641.28	[illegible]
[illegible]	28,481,495.22	[illegible]
[illegible]	360,379.52	[illegible]
[illegible]	149,611,261.72	[illegible]

Notes to the Financial Statements

(XXVIII) Non-current liabilities due within one year

Items	Balance as at the end of the period	[illegible]
[illegible]	180,020,000.00	[illegible]
[illegible]	41,747,868.00	[illegible]
[illegible]	28,643,888.99	[illegible]
[illegible]	250,411,756.99	[illegible]

(XXIX) Long-term borrowings

Items	Balance as at the end of the period	[illegible]
[illegible]	212,842,127.25	[illegible]
[illegible]	252,010,000.00	[illegible]
[illegible]	272,887,087.44	
[illegible]	180,020,000.00	[illegible]
[illegible]	557,719,214.69	[illegible]

(XXX) Lease liabilities

Items	Balance as at the end of the period	[illegible]
[illegible]	163,239,532.76	[illegible]
[illegible]	163,239,532.76	[illegible]

Notes to the Financial Statements

(XXXI) Long-term payables

Items	Balance as at the end of the period	
	61,351,340.53	[illegible]
	61,351,340.53	[illegible]

Items	Balance as at the end of the period	
	103,099,208.53	[illegible]
	15,109,210.13	[illegible]
	41,747,868.00	[illegible]
	61,351,340.53	[illegible]

(XXXII) Deferred income

Items				Balance as at the end of the period	
	[illegible]		[illegible]	8,734,099.00	
	[illegible]		[illegible]	8,734,099.00	

Notes to the Financial Statements

(XXXIII)Share capital

Items					Balance as at the end of the period
[illegible]	[illegible]				74,600,300.00

(XXXIV)Capital surplus

Items				Balance as at the end of the period
[illegible]	[illegible]		[illegible]	781,037,804.26
[illegible]	[illegible]			44,857,374.20
	[illegible]			26,800,423.23
[illegible]	[illegible]		[illegible]	852,695,601.69

Notes to the Financial Statements

(XXXV) Treasury stock

Items	[illegible]	[illegible]	[illegible]	Balance as at the end of the period
[illegible]		[illegible]		12,587,011.74
[illegible]		[illegible]		12,587,011.74

(XXXVI) Surplus reserve

Items	[illegible]	[illegible]	[illegible]	Balance as at the end of the period
[illegible]	[illegible]			38,399,577.13
[illegible]	[illegible]			38,399,577.13

(XXXVIII) Revenue and cost of sales

	Amount for the current period		[illegible]	
	Revenue	Cost		
	1,485,160,594.55	1,107,920,076.52	[illegible]	[illegible]
	111,104,937.58	77,209,878.26	[illegible]	[illegible]
	1,596,265,532.13	1,185,129,954.78	[illegible]	[illegible]

Items	Amount for the current period	[illegible]
	1,485,160,594.55	[illegible]
	1,485,160,594.55	[illegible]
	111,104,937.58	[illegible]
	64,381,373.94	[illegible]
	2,970,297.01	[illegible]
	5,348,551.23	[illegible]
	38,404,715.40	[illegible]
	1,596,265,532.13	[illegible]

Item	Time for fulfilment of obligations	Significant payment terms	Nature of the Company's transfer of the promised goods	Whether the Company is acting as principal	Amounts assumed by the Company that are expected to be refunded to customers	Types of quality assurance provided by the Company and relevant obligations
	[illegible]		[illegible]		[illegible]	[illegible]

Notes to the Financial Statements

(XXXIX) Taxes and surcharges

Items	Amount for the current period	[illegible]
[illegible]	3,840,629.56	[illegible]
[illegible]	999,802.54	[illegible]
[illegible]	715,238.61	[illegible]
[illegible]	591,575.87	[illegible]
[illegible]	236,151.41	[illegible]
[illegible]	91,506.43	[illegible]
[illegible]	6,474,904.42	[illegible]

(XL) Selling and distribution expenses

Items	Amount for the current period	[illegible]
[illegible]	9,997,218.22	[illegible]
[illegible]	187,939.95	[illegible]
[illegible]	45,063.22	[illegible]
[illegible]	310,251.33	[illegible]
[illegible]	557,306.00	[illegible]
[illegible]	454,630.25	[illegible]
[illegible]	380,695.34	[illegible]
[illegible]	299,196.27	[illegible]
[illegible]	4,499,117.73	[illegible]
[illegible]	26,633.57	[illegible]
[illegible]	211,141.96	[illegible]
[illegible]	133,161.25	[illegible]
[illegible]	17,102,355.09	[illegible]

Notes to the Financial Statements

[illegible]

(XLI) General and administrative expenses

Items	Amount for the current period	[illegible]
[illegible]	117,426,249.41	[illegible]
[illegible]	14,340,685.87	[illegible]
[illegible]	16,053,053.39	[illegible]
[illegible]	11,808,114.41	[illegible]
[illegible]	9,295,943.53	[illegible]
[illegible]	5,512,000.00	[illegible]
[illegible]	5,352,023.47	[illegible]
[illegible]	3,751,610.40	[illegible]
[illegible]	5,412,016.04	[illegible]
[illegible]		[illegible]
[illegible]	4,724,842.42	[illegible]
[illegible]	4,210,351.64	[illegible]
[illegible]	2,276,807.42	[illegible]
[illegible]	336,383.83	[illegible]
[illegible]	2,862,423.39	[illegible]
[illegible]	2,356,838.11	[illegible]
[illegible]	1,038,793.97	[illegible]
[illegible]	6,267,569.84	[illegible]
[illegible]	213,025,707.14	[illegible]

Notes to the Financial Statements

(XLII) Research and development expenses

Items	Amount for the current period	[illegible]
[illegible]	30,617,367.73	[illegible]
[illegible]	418,828.66	[illegible]
[illegible]	624,385.94	[illegible]
[illegible]	152,451.48	[illegible]
[illegible]		[illegible]
[illegible]	18,963.20	[illegible]
[illegible]	47,787.71	[illegible]
[illegible]	21,880.00	[illegible]
[illegible]	7,034.07	[illegible]
[illegible]	6,591.50	[illegible]
[illegible]	13,781.04	[illegible]
[illegible]	537,124.82	[illegible]
[illegible]	32,466,196.15	[illegible]

(XLIII) Financial expenses

Items	Amount for the current period	[illegible]
[illegible]	39,936,115.20	[illegible]
[illegible]	9,189,724.07	[illegible]
[illegible]	5,265,571.27	[illegible]
[illegible]	-4,325.27	[illegible]
[illegible]	1,091,522.53	[illegible]
[illegible]	5,694,269.99	[illegible]
[illegible]	41,452,011.18	[illegible]

Notes to the Financial Statements

(XLIV) Other income

Items	Amount for the current period	[illegible]
[illegible]	15,747,206.89	[illegible]
[illegible]	37,292.41	[illegible]
[illegible]	192,215.93	[illegible]
		[illegible]
[illegible]	15,976,715.23	[illegible]

(XLV) Investment income

Items	Amount for the current period	[illegible]
[illegible]	-6,465,278.89	[illegible]
[illegible]	697,750.03	[illegible]
[illegible]		[illegible]
[illegible]	-299,668.37	
[illegible]	-6,067,197.23	[illegible]

Notes to the Financial Statements

(XLVI) Gains from changes in fair value

Source of gains from changes in fair value	Amount for the current period	
	-3,290,727.47	
	1,522,929.38	
	1,982,203.29	
	214,405.20	

(XLVII) Credit impairment losses

Items	Amount for the current period	
	7,172,896.37	
	2,181,839.18	
	9,354,735.55	

(XLVIII) Assets impairment losses

Items	Amount for the current period	

(XLIX) Gains from disposal of assets

Items	Amount for the current period	[illegible]	[illegible]
[illegible]	68,088.99	[illegible]	[illegible]
[illegible]	68,088.99	[illegible]	[illegible]
[illegible]	68,088.99	[illegible]	[illegible]

(L) Non-operating income

Items	Amount for the current period	[illegible]	[illegible]

Notes to the Financial Statements

[illegible]

[illegible]

(LI) Non-operating expenses

Items	Amount for the current period	[illegible]	[illegible]
[illegible]			
[illegible]	291,184.61	[illegible]	[illegible]
[illegible]	291,184.61	[illegible]	[illegible]
[illegible]	4,494,074.74	[illegible]	[illegible]
[illegible]	264,009.83	[illegible]	[illegible]
[illegible]	41,926.44	[illegible]	[illegible]
[illegible]	2,183,827.02	[illegible]	[illegible]
[illegible]	4,111,097.80	[illegible]	[illegible]
[illegible]	429,388.42	[illegible]	[illegible]
[illegible]	11,815,508.86	[illegible]	[illegible]

Notes to the Financial Statements

(LII) Income tax expenses

Items	Amount for the current period	[illegible]
[illegible]	36,259,411.49	[illegible]
[illegible]	-24,009,402.00	[illegible]
[illegible]	12,250,009.49	[illegible]

Items	Amount for the current period
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	
[illegible]	[illegible]
[illegible]	
[illegible]	[illegible]
[illegible]	
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
	[illegible]
[illegible]	[illegible]

Notes to the Financial Statements

(LIII) Earnings per share

Items	Amount for the current period	[illegible]
[illegible]	85,947,806.64	[illegible]
[illegible]	74,600,300.00	[illegible]
[illegible]	1.15	[illegible]
[illegible]	1.15	[illegible]

Items	Amount for the current period	[illegible]
[illegible]	85,947,806.64	[illegible]
[illegible]	74,600,300.00	[illegible]
[illegible]	1.15	[illegible]
[illegible]	1.15	[illegible]

Notes to the Financial Statements

(LIV) Items in the cash flow statement

Items	Amount for the current period	[illegible]
[illegible]	14,853,235.92	[illegible]
[illegible]	16,214,614.27	[illegible]
[illegible]	5,348,551.23	[illegible]
[illegible]	8,222,606.16	[illegible]
[illegible]	3,014,649.40	[illegible]
[illegible]	2,808,105.11	[illegible]
[illegible]		[illegible]
[illegible]	164,796,135.37	
[illegible]	215,257,897.46	[illegible]

Items	Amount for the current period	[illegible]
[illegible]	67,255,904.20	[illegible]
[illegible]	80,394,069.79	[illegible]
[illegible]	6,741,690.53	[illegible]
[illegible]	3,747,445.03	[illegible]
[illegible]	1,111,874.54	[illegible]
[illegible]	1,635,289.27	[illegible]
	10,320,319.28	
[illegible]	165,915,458.06	
[illegible]	337,122,050.70	[illegible]

Notes to the Financial Statements

(LIV) Items in the cash flow statement

Items	Amount for the current period	[illegible]
[illegible]	276,383.95	
[illegible]	971,616.05	
[illegible]	1,248,000.00	

Items	Amount for the current period	[illegible]
[illegible]	500,059.94	[illegible]
[illegible]	13,500,000.00	
[illegible]	14,000,059.94	[illegible]

Items	Amount for the current period	[illegible]
[illegible]	55,000,000.00	[illegible]
[illegible]		[illegible]
[illegible]	900,000.00	
[illegible]	55,900,000.00	[illegible]

Notes to the Financial Statements

(LIV) **Items in the cash flow statement**

Items	Amount for the current period	[illegible]
[illegible]	100,045,828.93	[illegible]
[illegible]	49,299,788.06	[illegible]
[illegible]		[illegible]
[illegible]	2,656,500.00	
[illegible]		
[illegible]	4,866,900.00	
[illegible]	18,621,600.00	
[illegible]	175,490,616.99	[illegible]

Items	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	Balance as at the end of the period
[illegible]	[illegible]	[illegible]		[illegible]		127,001,700.00
[illegible]	[illegible]	[illegible]		[illegible]		737,739,214.69
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	191,883,421.75
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	103,099,208.53

Notes to the Financial Statements

[illegible]

(LV) Supplementary information to the cash flow statement

[illegible]

Supplementary information	Amount for the current period	[illegible]
[illegible]		
[illegible]	85,947,806.64	[illegible]
[illegible]	983,801.18	
[illegible]	9,354,735.55	[illegible]
[illegible]		[illegible]
[illegible]	47,460,771.26	[illegible]
[illegible]		
[illegible]		
[illegible]	40,597,483.20	[illegible]
[illegible]	25,492,057.82	[illegible]
[illegible]	45,839,280.77	[illegible]
[illegible]		
[illegible]	297,499.85	[illegible]
[illegible]	258,328.74	[illegible]
[illegible]	-214,405.20	[illegible]
[illegible]	40,800,972.44	[illegible]
[illegible]	6,067,197.24	[illegible]
[illegible]	-18,371,099.67	[illegible]
[illegible]	-5,638,302.33	[illegible]
[illegible]	4,376,940.05	[illegible]
[illegible]		

Notes to the Financial Statements

(LV) Supplementary information to the cash flow statement

	Amount
[illegible]	
[illegible]	33,716,662.00
[illegible]	15,500,000.00
[illegible]	14,510,000.00
[illegible]	3,456,662.00
[illegible]	250,000.00
[illegible]	2,427,508.68
[illegible]	562,986.94
[illegible]	607,690.86
[illegible]	1,256,830.88
[illegible]	
[illegible]	
[illegible]	
[illegible]	
[illegible]	
[illegible]	
[illegible]	
[illegible]	31,289,153.32

Items	Balance as at the end of the period	[illegible]
[illegible]	404,723,339.37	[illegible]
[illegible]	371,623.69	[illegible]
[illegible]	402,841,916.96	[illegible]
[illegible]	1,509,798.72	[illegible]
[illegible]		
[illegible]	404,723,339.37	[illegible]
[illegible]		

(LV) Supplementary information to the cash flow statement

Items	Balance as at the end of the period		
	772,510.54		
	12,000,000.00		
	1,361,750.73		
	2,120.75		
	2,000.00		
	14,138,382.02		

(LVI) Notes to items of statement of changes in owners' equity

(LVII) Foreign currency monetary items

Item	Closing balance denominated in foreign currency		
	133,966.54		
	81,905.11		
	52,061.43		

Notes to the Financial Statements

(LVIII) Lease

Item	Amount for the current period	[illegible]
[illegible]	9,189,724.07	[illegible]
[illegible]	49,299,788.06	[illegible]
[illegible]	55,000,000.00	[illegible]
[illegible]	100,045,828.93	[illegible]

Operating lease	Amount for the current period	[illegible]
[illegible]	5,348,551.23	[illegible]

(I) Business combination not under common control

Name of acquiree	Time of acquisition of equity interest	Consideration of acquisition of equity interest	Percentage of equity interest acquired (%)	Method of acquisition of equity interest	Date of acquisition	Basis for determining the date of acquisition	Income of the acquiree from the date of acquisition to the end of the period	Net profit of the acquiree from the date of acquisition to the end of the period	Cash flow of the acquiree from the date of acquisition to the end of the period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]			

[illegible] 重慶金浦醫療產業投資有限公司 [illegible]

(I) Business combination not under common control

(I) Business combination not under common control

Notes to the Financial Statements

(I) Business combination not under common control

(I) Business combination not under common control

Name of acquiree	Time of acquisition for equity interest previously held prior to the date of acquisition	Percentage of acquisition for equity interest previously held prior to the date of acquisition	Cost of acquisition for equity previously held prior to the date of acquisition	Method of acquisition for equity previously held prior to the date of acquisition	Carrying value on the date of acquisition for equity previously held prior to the date of acquisition	Fair value on the date of acquisition for equity previously held prior to the date of acquisition	Gains or losses arising from the remeasurement of equity previously held at fair value prior to the date of acquisition	Method and main assumptions of determining the fair value on the date of acquisition for equity previously held prior to the date of acquisition	Amounts transferred to investment income/ retained earnings from other comprehensive income related to equity previously held prior to the date of acquisition
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]	[illegible]	

(II) Disposal of subsidiaries

Notes to the Financial Statements

(III) Changes in the scope of consolidation due to other reasons

Notes to the Financial Statements

(I) Interests in subsidiaries

[illegible]	Type of legal entity	Registered capital (0000' yuan)	Principal place of business	Place of registration	Nature of business	Shareholding (%) Direct	Shareholding (%) Indirect	Method of acquisition
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
溫州傑鑈靖心科技有限公司	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(I) Interests in subsidiaries

	Type of legal entity	Registered capital (0000' yuan)	Principal place of business	Place of registration	Nature of business	Shareholding (%) Direct	Method of acquisition
浦江怡寧黃鋒醫院有限公司							

Notes to the Financial Statements

(I) Interests in subsidiaries

[illegible]	Type of legal entity	Registered capital (0000' yuan)	Principal place of business	Place of registration	Nature of business	Shareholding (%) Direct	Method of acquisition
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]				[illegible]	[illegible]
[illegible]	[illegible]	[illegible]				[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
[illegible]	[illegible]	[illegible]			[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]				[illegible]	[illegible]

Notes to the Financial Statements

(I) Interests in subsidiaries

Name of subsidiary	Shareholding percentage of non-controlling shareholder	Current profits or losses attributable to non-controlling shareholders	Current dividends distributed to non-controlling shareholders	Closing balance of interest of non-controlling shareholders
[illegible]	[illegible]	[illegible]		[illegible]
[illegible]	[illegible]	[illegible]		[illegible]
[illegible]	[illegible]	[illegible]		[illegible]

(I) Interests in subsidiaries

Name of subsidiary	Balance as at the end of the period: Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities						
[illegible]	12,771,926.28	126,317,515.02	139,089,441.30	48,340.35	75,123,750.00	75,172,090.35	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	13,868,975.32	71,012,513.90	84,881,489.22	15,643,448.52	28,680,000.20	44,323,448.72	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	9,462,168.42	26,252,849.68	35,715,018.10	1,026,823.83	4,385,658.39	5,412,482.22						

Name of subsidiary	Amount for the current period: Revenue	Net profit	Total comprehensive income	Cash flows from operating activities	Amount for the previous period: Revenue	Net profit	Total comprehensive income	Cash flows from operating activities
[illegible]		-1,000,974.74	-1,000,974.74	-3,869,458.16		[illegible]	[illegible]	[illegible]
[illegible]	16,050,977.70	-2,852,161.57	-2,852,161.57	-8,603,908.46	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	6,257,706.23	466,316.48	466,316.48	1,112,871.98				

(II) Transactions that cause changes in the share of owners' equity in subsidiaries that do not result in loss of control

	Linhai Kangning	Jinyun Shuning
[illegible]		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]		
[illegible]		

(III) Interests in joint ventures or associates

Items	Closing balance/amount for the current period: Hangzhou Anken Medical Technology Co., Ltd.	Wenzhou Longwan Yining Hospital Co., Ltd.	Shaanxi Shanda Hospital Management Consulting Co., Ltd.	Opening balance/amount for the previous period: Hangzhou Anken Medical Technology Co., Ltd.	Wenzhou Longwan Yining Hospital Co., Ltd.	Shaanxi Shanda Hospital Management Consulting Co., Ltd.
	53,708,669.65	46,656,767.88	71,300,257.36	[illegible]	[illegible]	[illegible]
	46,709,884.95	152,199,429.22	117,230,334.02	[illegible]	[illegible]	[illegible]
	100,418,554.60	198,856,197.10	188,530,591.38	[illegible]	[illegible]	[illegible]
	54,935,249.19	37,541,901.86	97,460,588.12	[illegible]	[illegible]	[illegible]
	15,050,976.27	35,000,000.00	15,000,000.00	[illegible]		
	69,986,225.46	72,541,901.86	112,460,588.12	[illegible]	[illegible]	[illegible]
	4,751,694.63		19,343,974.26			
	25,680,634.51	126,314,295.24	56,726,029.00	[illegible]	[illegible]	[illegible]
	9,376,542.33	56,841,432.86	22,821,000.98	[illegible]	[illegible]	[illegible]
	140,281,463.89		47,654,671.86	[illegible]		[illegible]
	6,903,036.00	-257,993.98	1,052,984.93	[illegible]	[illegible]	[illegible]
	6,903,036.00	-257,993.98	1,052,984.93	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(I) Types, amounts and presentation items of government grants

Items included in profit or loss for the current period or offset against related cost and expense losses	Government grants amount	The amount included in profit or loss for the current period or offset against related cost and expense losses: Amount for the current period	Amount for the previous period
[illegible]	[illegible]	6,174,393.49	
[illegible]	[illegible]	1,808,866.20	
[illegible]	[illegible]	1,607,644.57	[illegible]
[illegible]	[illegible]	891,305.79	
[illegible]	[illegible]	785,833.31	[illegible]
[illegible]	[illegible]	710,750.00	
[illegible]	[illegible]	997,071.49	[illegible]
[illegible]	[illegible]	499,320.00	
[illegible]	[illegible]	344,000.00	[illegible]
[illegible]	[illegible]	303,792.00	[illegible]
[illegible]	[illegible]	280,000.00	
[illegible]	[illegible]	206,153.66	
[illegible]	[illegible]	203,186.30	[illegible]
[illegible]	[illegible]	200,000.00	[illegible]
[illegible]	[illegible]	171,500.00	

Notes to the Financial Statements

(I) Types, amounts and presentation items of government grants

Items included in profit or loss for the current period or offset against related cost and expense losses	Government grants amount	The amount included in profit or loss for the current period or offset against related cost and expense losses — Amount for the current period	Amount for the previous period
[illegible]	[illegible]	154,811.73	[illegible]
[illegible]	[illegible]	167,287.64	[illegible]
[illegible]	[illegible]	133,469.31	[illegible]
[illegible]	[illegible]	130,000.00	[illegible]
[illegible]	[illegible]	80,000.00	
[illegible]	[illegible]	53,200.00	
[illegible]	[illegible]	53,000.00	[illegible]
[illegible]	[illegible]	50,000.00	[illegible]
[illegible]	[illegible]	42,000.00	[illegible]
[illegible]	[illegible]	40,000.00	[illegible]
[illegible]	[illegible]	38,900.00	
[illegible]	[illegible]	34,500.00	[illegible]
[illegible]	[illegible]	30,000.00	
[illegible]	[illegible]	29,900.00	[illegible]
[illegible]	[illegible]	7,000.00	[illegible]

Notes to the Financial Statements

[illegible]

[illegible]

(I) Types, amounts and presentation items of government grants [illegible]

[illegible]

Items included in profit or loss for the current period or offset against related cost and expense losses	Government grants amount	The amount included in profit or loss for the current period or offset against related cost and expense losses: Amount for the current period	The amount included in profit or loss for the current period or offset against related cost and expense losses: Amount for the previous period
[illegible]	[illegible]	6,700.00	[illegible]
[illegible]	[illegible]	78,742.36	[illegible]
[illegible]	[illegible]	16,313,327.85	[illegible]

Notes to the Financial Statements

(I) Types, amounts and presentation items of government grants

Liabilities	Balance as at the end of the previous year	Additions of grants for the current period	Amount included in non-operating income for the current period	Amount transferred to other income for the current period	Amount of cost and expense offset for the current period	Other changes	Balance as at the end of the period	Asset-related/ income-related
[illegible]	[illegible]			[illegible]			[illegible]	[illegible]

(I) Various risks arise from financial instruments

Notes to the Financial Statements

(I) Various risks arise from financial instruments

Notes to the Financial Statements

(I) Various risks arise from financial instruments

	Instant repayment	Within 1 year	1-2 years	2-5 years	Over 5 years	Total undiscounted contractual amount	Carrying amount
				Balance as at the end of the period			
		1,545,021.09				1,545,021.09	1,545,021.09
		340,005,699.32	270,474,264.25	228,670,426.19	158,782,942.13	997,933,331.89	864,740,914.69
		28,643,888.99	44,408,365.80	71,261,748.80	69,158,488.54	213,472,492.13	191,883,421.75
		43,175,648.00	19,331,148.00	55,701,622.66		118,208,418.66	103,099,208.53
		110,060,007.67				110,060,007.67	110,060,007.67
		150,270,575.15				150,270,575.15	150,270,575.15
		673,700,840.22	334,213,778.05	355,633,797.65	227,941,430.67	1,591,489,846.59	1,421,599,148.88

Items	Instant repayment	Within 1 year	1-2 years	2-5 years	Over 5 years	Total undiscounted contractual amount	Carrying amount
				Balance as at the end of the previous year			
		[illegible]				[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]		[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(I) Various risks arise from financial instruments

Notes to the Financial Statements

(I) Various risks arise from financial instruments

Notes to the Financial Statements

(I) **Various risks arise from financial instruments**

[illegible]

(I) Closing fair value of assets and liabilities measured at fair value

Item	Closing fair value Measured at fair value at Level 1	Measured at fair value at Level 2	Measured at fair value at Level 3	Total
I. Continuous measurement of fair value				
◆ [illegible]			7,350,298.53	7,350,298.53
[illegible]			7,350,298.53	7,350,298.53
[illegible]			7,350,298.53	7,350,298.53
[illegible]				
◆ [illegible]			65,099,055.34	65,099,055.34
Total assets with continuous measurement of fair value			72,449,353.87	72,449,353.87
◆ [illegible]			12,400,000.00	12,400,000.00
[illegible]			12,400,000.00	12,400,000.00
[illegible]			12,400,000.00	12,400,000.00
[illegible]				
Total liabilities with continuous measurement of fair value			12,400,000.00	12,400,000.00

(II) Qualitative and quantitative information of valuation techniques and key parameters adopted for items measured at the fair value of level 3 on a going and non-going concern

[illegible]

[illegible]

Notes to the Financial Statements

(I) Information of the parent company

(II) Information of the Company's subsidiaries

(III) Information of the Company's joint ventures and associates

Name of joint venture or associate	Relationship with the Company

(IV) Information of other related parties

[illegible]	Other related parties' relationship with the Company
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]

Notes to the Financial Statements

(V) Information on related party transactions

Related party	Related party transaction particulars	Amount for the current period	Transaction cap approved	Whether exceeding transaction cap	Amount for the previous period
		62,492.04			
		261,708.62			
		88,727.40			
		285,284.00			
		1,125,496.02			
		388,089.38			
		650.00			

Related party	Related party transaction particulars	Amount for the current period	Amount for the previous period
		61,320.76	
		[illegible]	1,472,112.00
		790,027.40	
		193,990.06	
		635,000.00	
		2,970,297.00	[illegible]

Notes to the Financial Statements

(V) Information on related party transactions

Related parties	Placement amount	Commencement date	Expiry date	Description
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Item	Amount for the current period	Amount for the previous period
[illegible]	8,642,653.48	[illegible]

Notes to the Financial Statements

(V) Information on related party transactions

Name of guaranteed party	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(V) Information on related party transactions

Name of guarantor	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(V) Information on related party transactions

Name of guarantor	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

(VI) Receivables from and payables to related parties and other unsettled items

Items	Related parties	Balance as at the end of the period: Book balance	Balance as at the end of the period: Provision for bad debts	Balance as at the end of the previous year: Book balance	Balance as at the end of the previous year: Provision for bad debts
[illegible]	[illegible]	65,000.00	3,250.00		
	[illegible]	1,522.85	15.23		
	洛南善達康復醫院有限公司	635,000.00	6,350.00		
	義烏精神衛生中心	12,000,000.00	5,520,000.00	[illegible]	[illegible]
	[illegible]	23,709,977.64	17,002,735.51	[illegible]	[illegible]
	[illegible]	14,290,027.40	714,501.37		
	四川省宏濟藥業有限責任公司	10,204,311.69	10,204,311.69		
	汪長勝	3,490,447.08	3,490,447.08		
	[illegible]	16,836.66	841.83		
	陳光洪	100,000.00	1,000.00	[illegible]	[illegible]
	徐秀虎	80,004.00	800.04	[illegible]	[illegible]
	蔡文琴	105,187.50	5,259.38	[illegible]	[illegible]
	江丹平	479,707.50	23,985.38	[illegible]	[illegible]
[illegible]	[illegible]			[illegible]	

Notes to the Financial Statements

(VI) Receivables from and payables to related parties and other unsettled items

Items	Related parties	Book balance as at the end of the period	
		167,677.40	
		3,702,846.16	
		962,492.04	
		3,599,626.28	
		1,095,000.00	
		1,095,000.00	

Chongq80 1 Tfehab NTf0b441CS1 02B0nd56 Port Area K31zon .776080 1 Tfehab(arti22 (Invest/T1 d.)Tj/T1 P.11nership1 gs/.i2

Chongq80 1 Tfehab G31 We Co776 0 Td(1,095,0022Tj/T1 ,991 T.8291.776 -1.556 Td(Cho22T0 1 Tfehab Zhejf3g Y3gge ProTfcond

Notes to the Financial Statements

(VII)Interests and equity of the Directors

Name	Emoluments	Salaries and subsidies	Contributions to social security plans	Bonus	Other welfare	Total
Executive directors						
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Non-executive directors						
[illegible]						
[illegible]						
Independent directors						
[illegible]	[illegible]					[illegible]
[illegible]	[illegible]					[illegible]
[illegible]	[illegible]					[illegible]
[illegible]	[illegible]					[illegible]
[illegible]	[illegible]					[illegible]
Supervisors						
[illegible]						
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Total	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

(VII) Interests and equity of the Directors

Name	Emoluments	Salaries and subsidies	Contributions to social security plans	Bonus	Other welfare	Total
Executive directors						
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]		[illegible]	[illegible]
Non-executive directors						
[illegible]						
[illegible]						
Independent directors						
[illegible]	[illegible]					[illegible]
[illegible]	[illegible]					[illegible]
[illegible]	[illegible]					[illegible]
Supervisors						
[illegible]						
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Total	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

(VIII) Five Individuals with Highest Remunerations

[illegible]

	Amount for the current period	[illegible]
[illegible]	4,673,793.71	[illegible]
[illegible]	4,673,793.71	[illegible]

Notes to the Financial Statements

(VIII) Five Individuals with Highest Remunerations

Remuneration band	Number of individuals for the current period	Number of individuals for the previous period
[illegible]	4	[illegible]
[illegible]	1	[illegible]
[illegible]	5	[illegible]

(I) Summary of share-based payment

(II) Equity-settled share-based payment

Notes to the Financial Statements

(I) Significant commitments

	December 31, 2023	
	122,040,000.00	
	122,040,000.00	

(II) Contingencies

(I) Profit distribution

(II) Description of other events after the balance sheet date

Notes to the Financial Statements

	Balance as at the end of the period		
	53.93%		

(I) Segment Information

Notes to the Financial Statements

(II) Main impact of the implementation of Preparation Rules for Information Disclosure by Companies Offering Securities to the Public No. 15 — General Provisions on Financial Reports (2023 Revision)

(III) Other significant issues which influence the decision-making of investors

Notes to the Financial Statements

(I) Accounts receivable

Aging	Balance as at the end of the period	Balance as at the end of the previous year
[illegible]	48,552,078.47	[illegible]
[illegible]	257,315.13	[illegible]
[illegible]	709,878.26	[illegible]
[illegible]	3,906,521.87	[illegible]
[illegible]	53,425,793.73	[illegible]
[illegible]	5,359,236.04	[illegible]
[illegible]	48,066,557.69	[illegible]

(I) Accounts receivable [illegible]

Category	Balance as at the end of the period: Book balance: Amount	Balance as at the end of the period: Book balance: Proportion (%)	Balance as at the end of the period: Provision for bad debts: Amount	Balance as at the end of the period: Provision for bad debts: Proportion of provision (%)	Balance as at the end of the period: Carrying amount	Balance as at the end of the previous year: Book balance: Amount	Balance as at the end of the previous year: Book balance: Proportion (%)	Balance as at the end of the previous year: Provision for bad debts: Amount	Balance as at the end of the previous year: Provision for bad debts: Proportion of provision (%)	Balance as at the end of the previous year: Carrying amount
[illegible]	4,873,715.26	9.12	4,873,715.26	100.00		[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	4,873,715.26	9.12	4,873,715.26	100.00		[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	48,552,078.47	90.88	485,520.78	1.00	48,066,557.69	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	48,552,078.47	90.88	485,520.78	1.00	48,066,557.69	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	53,425,793.73	100.00	5,359,236.04	/	48,066,557.69	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Item	Balance as at the end of the period: Book balance	Balance as at the end of the period: Provision for bad debts	Balance as at the end of the period: Proportion of provision (%)	Balance as at the end of the period: Reason for the provision	Balance as at the end of the previous year: Book balance	Balance as at the end of the previous year: Provision for bad debts
[illegible]	4,873,715.26	4,873,715.26	100.00	Expected unrecoverable	[illegible]	[illegible]
[illegible]	4,873,715.26	4,873,715.26	/	/	[illegible]	[illegible]

Notes to the Financial Statements

(II) Other receivables

Items	Balance as at the end of the period	Balance as at the end of the previous year
[illegible]	14,400,000.00	[illegible]
[illegible]	586,048,325.58	[illegible]
[illegible]	600,448,325.58	[illegible]

Investees	Balance as at the end of the period	Balance as at the end of the previous year
[illegible]	4,400,000.00	[illegible]
[illegible]		[illegible]
[illegible]	10,000,000.00	[illegible]
[illegible]	14,400,000.00	[illegible]
[illegible]		
[illegible]	14,400,000.00	[illegible]

[illegible]	Balance as at the end of the period	[illegible]
[illegible]	552,853,728.97	[illegible]
[illegible]	34,594,797.65	[illegible]
[illegible]	496,167.22	[illegible]
[illegible]	908,479.96	[illegible]
[illegible]	588,853,173.80	[illegible]
[illegible]	2,804,848.22	[illegible]
[illegible]	586,048,325.58	[illegible]

(II) Other receivables

Category	Balance as at the end of the period					Balance as at the end of the previous year				
	Book balance		Provision for bad debts			Book balance		Provision for bad debts		
	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value
[illegible]	588,853,173.80	100.00	2,804,848.22	0.48	586,048,325.58	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	75,462,768.59	12.82	2,804,848.22	3.72	72,657,920.37	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	513,390,405.21	87.18			513,390,405.21	[illegible]	[illegible]			[illegible]
[illegible]	588,853,173.80	100.00	2,804,848.22	/	586,048,325.58	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

[illegible]

(II) Other receivables [illegible]

[illegible]

Provision for bad debts	Stage I 12-month ECL	Stage II Lifetime ECL (No credit impairment)	Stage III Lifetime ECL (Credit-impaired)	Total
[illegible]	[illegible]			[illegible]
[illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
[illegible]	[illegible]			[illegible]
[illegible]				
[illegible]				
[illegible]				
[illegible]				
[illegible]	[illegible]			[illegible]

(II) Other receivables

Book balance	Stage I 12-months ECL	Stage II Lifetime ECL (No credit impairment)	Stage III Lifetime ECL (Credit-impaired)	Total
[illegible]	[illegible]			[illegible]
[illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
— [illegible]				
[illegible]	[illegible]			[illegible]
[illegible]				
[illegible]	[illegible]			[illegible]

(II) Other receivables

		2,804,848.22
		2,804,848.22

Nature	Book balance at the end of the period	
	513,390,405.21	
	20,480,175.04	
	5,920,030.00	
	767,065.13	
	48,295,498.42	
	588,853,173.80	

(III) Long-term equity investments

Items	Balance as at the end of the period: Book balance	Provision for impairment	Book value			
	691,561,513.66		691,561,513.66			
	94,421,925.51		94,421,925.51			
	785,983,439.17		785,983,439.17			

(III) Long-term equity investments

Investees	Balance as at the end of the previous year	Balance of the impairment provision as at the end of the previous year	Increase/decrease in the current period: Increase in investment	Decrease in investment	Provision for impairment for the current period	Others	Balance as at the end of the period	Balance of the impairment provision as at the end of the period
[illegible]	[illegible]			[illegible]				
[illegible]			[illegible]				15,500,000.00	
[illegible]	[illegible]						500,000.00	
[illegible]	[illegible]						204,666,253.87	
[illegible]	[illegible]		[illegible]	[illegible]			52,697,737.50	
[illegible]	[illegible]						2,133,258.38	
[illegible]	[illegible]						27,687,093.11	
[illegible]	[illegible]						32,856,644.25	
[illegible]	[illegible]		[illegible]				4,799,071.39	
[illegible]	[illegible]						53,500,000.00	
[illegible]	[illegible]		[illegible]				40,800,000.00	
[illegible]	[illegible]						10,000,000.00	
[illegible]	[illegible]						154,744,700.00	
[illegible]	[illegible]		[illegible]				29,051,800.00	

Notes to the Financial Statements

(III) Long-term equity investments

Investees	Balance as at the end of the previous year	Balance of the impairment provision as at the end of the previous year	Increase/decrease in the current period: Increase in investment	Decrease in investment	Provision for impairment for the current period	Others	Balance as at the end of the period	Balance of the impairment provision as at the end of the period
[illegible]	[illegible]						40,954,955.16	
[illegible]			[illegible]				14,510,000.00	
[illegible]			[illegible]				500,000.00	
[illegible]			[illegible]				6,660,000.00	
[illegible]	[illegible]		[illegible]	[illegible]			691,561,513.66	

(III) Long-term equity investments

	Balance as at the end of the period
	16,018,884.98
	56,841,432.86
	21,561,607.67
	94,421,925.51

(IV) Revenue and cost of sales

Item	Amount for the current period Revenue	Cost		
	380,358,202.27	269,941,680.92		
	6,967,659.63			
	387,325,861.90	269,941,680.92		

Item	Time for fulfilment of obligations	Significant payment terms	Nature of the Company's transfer of the promised goods	Whether the Company is acting as principal	Amounts assumed by the Company that are expected to be refunded to customers	Types of quality assurance provided by the Company and relevant obligations

(V) Investment income

Item	Amount for the current period	
	35,000,000.00	
	1,538,932.70	
	-1,946,692.33	
	-299,668.37	
	34,292,572.00	

Definitions

北京怡寧醫院有限公司

蒼南康寧醫院有限公司

長春康林心理醫院有限公司

成都怡寧醫院有限公司

淳安康寧黃鋒醫院有限公司

Definitions

洞口樂寧醫院有限公司

溫州怡寧老年醫院有限公司

Definitions

淮南康寧醫院有限公司

縉雲舒寧醫院有限公司

婁底市康樂康寧醫院有限責任公司

溫州鹿城怡寧醫院有限公司

Definitions

臨海慈寧醫院有限公司

平陽長庚怡寧醫院有限公司

浦江怡寧黃鋒醫院有限公司

中華人民共和國公司法

青田康寧醫院有限公司

Definitions

衢州怡寧醫院有限公司

深圳怡寧醫院

深圳市怡寧醫院有限公司

Definitions

溫州慈寧醫院有限公司

溫州甌海怡寧老年醫院有限公司

怡寧心理互聯網醫院（溫州）有限公司

永嘉康寧醫院有限公司

樂清康寧醫院有限公司

樂清怡寧中西醫結合醫院有限公司

樂清邦爾中西醫結合醫院有限公司

溫州康寧醫院股份有限公司

Wenzhou Kangning Hospital Co., Ltd.